PURPOSE: The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpene POH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. PATIENTS AND METHODS: It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. RESULTS: Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. CONCLUSION: Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.
PURPOSE: The monoterpene perillyl alcohol (POH) a Ras inhibitor with potential capacity to arrest gliomagenesis is being used in a phase I/II clinical trial in adults with recurrent malignant glioma. The present study aimed to investigate the efficacy of intranasal administration of monoterpenePOH upon survival rate of patients with recurrent glioblastoma (GBM) in comparison with historical control group of GBM patients. PATIENTS AND METHODS: It was included 89 adults with recurrent GBM receiving daily intranasal administration of 440 mg POH and 52 matched GBM patients as historical control untreated group only with supportive treatment. RESULTS:Patients with recurrent primary GBM treated with POH survived significantly longer (log rank test, P < 0.0001) than untreated group. Patients with recurrent primary GBM in deep location survived significantly longer than with lobar location (log rank test, P < 0.0001). Median survival rate of secondary GBM was 11.2 months, longer (log rank test, P = 0.0366) than primary GBM (5.9 months). Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression. CONCLUSION: Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. The side effects of POH treatment were almost nonexistent, even in patients treated for over 4 years.
Authors: Clovis Orlando da Fonseca; José Alberto Landeiro; Steven S Clark; Thereza Quirico-Santos; Maria da Gloria da Costa Carvalho; Cerli Rocha Gattass Journal: Surg Neurol Date: 2006
Authors: Yuan Rong; Fang Hu; Ruopan Huang; Nigel Mackman; Jonathan M Horowitz; Randy L Jensen; Donald L Durden; Erwin G Van Meir; Daniel J Brat Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen Journal: Neuro Oncol Date: 2008-02-20 Impact factor: 12.300
Authors: Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo Journal: Proc Natl Acad Sci U S A Date: 2008-03-24 Impact factor: 11.205
Authors: Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim Journal: J Cancer Res Clin Oncol Date: 2012-04-06 Impact factor: 4.553
Authors: Marcela de Oliveira Silva; Graziella Ribeiro de Sousa; Sarah Capelupe Simões; Patrícia Nicolucci; Edwin Tamashiro; Fabiano Saggioro; Ricardo Santos de Oliveira; María Sol Brassesco Journal: Childs Nerv Syst Date: 2021-04-22 Impact factor: 1.475
Authors: Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis; Timothy Charles Ryken Journal: J Neurooncol Date: 2014-04-17 Impact factor: 4.130